Dostarlimab in combination with docetaxel is in clinical development for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have progressed on prior anti-PD(L)-1 therapy and chemotherapy. NSCLC is the most common type of lung cancer. Advanced cancer means it has spread around the body from where it started making it harder to treat and increasing rates of mortality. Symptoms include a cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness. Immunotherapy is one of the leading treatments for NSCLC, but it does not help many patients due to resistance, either from the start or developing later.
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after progression on anti-PD-L1 therapy and chemotherapy
Dostarlimab in combination with docetaxel is in clinical development for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have progressed on prior anti-PD(L)-1 therapy and chemotherapy.
Interventions:
Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous)
, Dostarlimab (TSR-042; Jemperli)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2024